Comparative prognosis of pediatric lymphoblastic lymphoma: insights from Chinese and international cohorts
Pediatric lymphoblastic lymphoma (LBL) is predominantly T-cell subtype (China: 77.9%, SEER: 64.4%) and frequently diagnosed at stage IV. Survival did not differ between B- and T-LBL, but China cohort patients treated in 2017-2019 had better outcomes than those in 2020-2023 (P<0.01), possibly linked to COVID-19 disruptions. No independent prognostic factors were identified, warranting larger studies integrating treatment details to refine risk stratification.
Authors
- Yongyan He (ORCID: https://orcid.org/0009-0001-5378-0915)
- Tianhui Chen (ORCID: https://orcid.org/0000-0003-4677-0361)
- Wei Liu (ORCID: https://orcid.org/0000-0001-6715-0490)
- Luyao Zhang (ORCID: https://orcid.org/0000-0002-3434-523X)
- Jianwen Zhou (ORCID: https://orcid.org/0009-0004-2927-239X)
Institutions
- Zhengzhou University (CN)
- Zhejiang Cancer Hospital (CN)
- Zhengzhou Children's Hospital (CN)
- Hangzhou Academy of Agricultural Sciences (CN)
- Zhengzhou Business University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fonc.2025.1626143
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00